Login to Your Account

KeyNeurotek Gets €8.2M for Overactive Bladder Program

By Cormac Sheridan

Wednesday, April 8, 2009

No Abstract


BioWorld International Correspondent

KeyNeurotek Pharmaceuticals AG completed a second closing of an internal Series C round, raising the total value of the deal to €8.2 million (US$10.9 million).

Although no new investors bought into the company, all its "main existing investors" did participate, Magdeburg, Germany-based KeyNeurotek said.

Those include Munich-based Deutsche Venture Capital, IBG Beteiligungsgesellschaft, of Magdeburg, and Bonn-based KfW.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription